Gene-Editing Transfection Chemicals Market Report 2026

The gene‑editing transfection chemicals market size has grown strongly in recent years. It will grow from $1.07 billion in 2025 to $1.16 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to limited availability of high-efficiency transfection chemicals, reliance on traditional delivery methods, growing academic and research institute activities, increasing investment in biotechnology research, early adoption of gene-editing tools.

The gene‑editing transfection chemicals market size is expected to see strong growth in the next few years. It will grow to $1.56 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to development of advanced lipid, polymer, and peptide-based chemicals, rising demand for precise gene-editing applications, expansion in pharmaceutical and biotechnology R&D, integration of automated transfection platforms, increasing regulatory approvals and standardized protocols. Major trends in the forecast period include rising adoption of lipid-based transfection chemicals, increased use of polymer and peptide-based delivery systems, growth in non-viral and viral delivery mechanisms, expansion of gene-editing applications in drug discovery and disease modeling, focus on improving transfection efficiency and cell viability.

The rapid advancement of research in gene therapy is anticipated to drive the growth of the gene-editing transfection chemicals market in the coming years. Gene therapy is a therapeutic approach aimed at treating or preventing diseases by directly altering or repairing defective genes within a patient’s cells. Research activity in gene therapy is accelerating due to major breakthroughs in gene-editing technologies such as CRISPR, which enable precise targeting and modification of faulty genes responsible for genetic disorders. Gene-editing transfection chemicals play a critical role in gene therapy research and development, as they facilitate the efficient delivery of genetic materials, including CRISPR-Cas9 components, mRNA, and plasmid DNA, into human cells. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, an increase from five approvals in 2022. Therefore, the acceleration of gene therapy research is contributing to the growth of the gene-editing transfection chemicals market.

Leading companies operating in the gene-editing transfection chemicals market are concentrating on the introduction of innovative solutions, such as lipid nanoparticle (LNP) starter kits, to simplify gene therapy and mRNA delivery workflows. Lipid nanoparticle (LNP) starter kits are ready-to-use formulations or toolsets that include pre-optimized lipid components and standardized protocols designed to support the development and testing of LNP-based delivery systems. For example, in February 2024, CordenPharma, a Switzerland-based pharmaceutical company, launched Lipid NanoParticle (LNP) Starter Kits to assist researchers and developers in formulating and optimizing mRNA-based therapeutics, including vaccines and gene therapies. These kits contain four essential lipid types, including ionizable lipids, helper lipids, sterols, and PEGylated lipids, derived from commercial-scale, high-purity materials to ensure batch-to-batch consistency and minimize the risk of losing high-value payloads during development. By offering a dependable and scalable lipid platform, CordenPharma seeks to accelerate gene editing and mRNA therapeutic development while protecting valuable genetic payloads.

In August 2024, Merck KGaA, a Germany-based science and technology company, acquired Mirus Bio LLC for $600 million. Through this acquisition, Merck aimed to further its objective of delivering fully integrated and end-to-end solutions across all stages of viral vector manufacturing, supporting the development and commercialization of cell and gene therapies from preclinical research to commercial production. Mirus Bio LLC is a US-based company that produces transfection reagents used in gene editing as well as other cell and gene therapy applications.

Major companies operating in the gene‑editing transfection chemicals market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Takara Bio Inc., Mirus Bio LLC, OZ Biosciences SAS, Genlantis Inc., Polyplus-Transfection SA, Altogen Biosystems LLC, SignaGen Laboratories.

North America was the largest region in the gene‑editing transfection chemicals market in 2025. The regions covered in the gene‑editing transfection chemicals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene‑editing transfection chemicals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the gene-editing transfection chemicals market by increasing the cost of imported high-purity reagents, specialized lipids, and polymer-based chemicals. Segments such as lipid-based and peptide-based transfection chemicals are particularly impacted, with regions like North America, Europe, and Asia-Pacific facing supply chain cost pressures. While tariffs have led to increased production costs and slowed adoption in some regions, they also encourage local production, development of alternative formulations, and investment in domestic manufacturing capabilities.

The gene‑editing transfection chemicals market research report is one of a series of new reports that provides gene‑editing transfection chemicals market statistics, including gene‑editing transfection chemicals industry global market size, regional shares, competitors with a gene‑editing transfection chemicals market share, detailed gene‑editing transfection chemicals market segments, market trends and opportunities, and any further data you may need to thrive in the gene‑editing transfection chemicals industry. This gene‑editing transfection chemicals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene-editing transfection chemicals are specialized agents designed to facilitate the effective delivery of gene-editing tools such as CRISPR-Cas9 complexes, plasmid DNA, or RNA molecules into living cells by assisting their passage across the cell membrane while preventing degradation. These chemicals play a crucial role in achieving high transfection efficiency and successful genome modification, as they safeguard the genetic material and support its cellular uptake, expression, and functional activity within target cells.

The key categories of gene-editing transfection chemicals include lipid-based, polymer-based, peptide-based, and others. Lipid-based gene-editing transfection chemicals are delivery agents made of lipid molecules that aid in transporting gene-editing tools, including CRISPR-Cas9, into target cells. These chemicals employ various delivery approaches, such as non-viral and viral methods, and are used across a broad range of applications, including biomedical research, drug discovery, disease modeling, agricultural biotechnology, vaccine development, and others. The major end users include academic and research institutions, biotechnology companies, pharmaceutical companies, and others.

The gene-editing transfection chemicals market consists of sales of products, including lipid-based transfection reagents, polymer-based transfection reagents, electroporation buffers and kits, nanoparticle-based delivery systems, and cell-specific transfection reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.